Equities analysts expect ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) to report sales of $1.20 million for the current quarter, Zacks Investment Research reports. Four analysts have made estimates for ZIOPHARM Oncology’s earnings. The lowest sales estimate is $150,000.00 and the highest is $1.60 million. ZIOPHARM Oncology posted sales of $1.60 million during the same quarter last year, which suggests a negative year-over-year growth rate of 25%. The firm is expected to report its next quarterly earnings results on Monday, July 30th.
According to Zacks, analysts expect that ZIOPHARM Oncology will report full year sales of $3.39 million for the current year, with estimates ranging from $590,000.00 to $4.94 million. For the next financial year, analysts forecast that the company will post sales of $7.96 million per share, with estimates ranging from $590,000.00 to $20.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover ZIOPHARM Oncology.
ZIOPHARM Oncology (NASDAQ:ZIOP) last issued its earnings results on Thursday, May 10th. The biotechnology company reported ($0.15) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by ($0.02). The business had revenue of $0.15 million during the quarter, compared to analysts’ expectations of $1.55 million.
ZIOP has been the subject of several research analyst reports. BidaskClub raised ZIOPHARM Oncology from a “strong sell” rating to a “sell” rating in a research note on Wednesday, April 4th. Zacks Investment Research downgraded ZIOPHARM Oncology from a “hold” rating to a “sell” rating in a research note on Thursday, March 15th. ValuEngine downgraded ZIOPHARM Oncology from a “sell” rating to a “strong sell” rating in a research note on Thursday, March 1st. Finally, HC Wainwright set a $10.00 target price on ZIOPHARM Oncology and gave the stock a “buy” rating in a research note on Monday, March 5th. Three research analysts have rated the stock with a sell rating, two have issued a hold rating and one has assigned a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus target price of $5.25.
Shares of NASDAQ ZIOP opened at $3.23 on Wednesday. The stock has a market cap of $455.06 million, a price-to-earnings ratio of -6.09 and a beta of 1.70. ZIOPHARM Oncology has a 12 month low of $2.98 and a 12 month high of $6.67.
Large investors have recently added to or reduced their stakes in the company. G&S Capital LLC bought a new stake in shares of ZIOPHARM Oncology during the fourth quarter worth about $125,000. Summit Trail Advisors LLC grew its holdings in shares of ZIOPHARM Oncology by 351.7% during the first quarter. Summit Trail Advisors LLC now owns 125,392 shares of the biotechnology company’s stock worth $125,000 after purchasing an additional 97,632 shares during the last quarter. Metropolitan Life Insurance Co. NY bought a new stake in shares of ZIOPHARM Oncology during the fourth quarter worth about $139,000. Teacher Retirement System of Texas grew its holdings in shares of ZIOPHARM Oncology by 302.7% during the fourth quarter. Teacher Retirement System of Texas now owns 42,517 shares of the biotechnology company’s stock worth $176,000 after purchasing an additional 31,958 shares during the last quarter. Finally, LPL Financial LLC grew its holdings in shares of ZIOPHARM Oncology by 257.1% during the fourth quarter. LPL Financial LLC now owns 46,343 shares of the biotechnology company’s stock worth $192,000 after purchasing an additional 33,366 shares during the last quarter. Institutional investors own 39.78% of the company’s stock.
About ZIOPHARM Oncology
ZIOPHARM Oncology, Inc, a biotechnology company, focuses on acquiring, developing, and commercializing a portfolio of immuno-oncology therapies for treating heterogenous solid tumors and unknown antigens. The company develops two immuno-oncology platform technologies, including Controlled IL-12, which delivers interleukin 12 or IL-12, a master regular of the immune system, in a controlled and safe manner to focus the patient's immune system to cancer; and Sleeping Beauty (SB), which is based on the genetic engineering of T-cells using the (SB) system to rapidly reprogram T-cells outside of the body for infusion.
Get a free copy of the Zacks research report on ZIOPHARM Oncology (ZIOP)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ZIOPHARM Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ZIOPHARM Oncology and related companies with MarketBeat.com's FREE daily email newsletter.